ライフサイエンスコーパス: controller

1 ow disease progression (also known as "elite controllers").

2 V in the absence of antiretroviral therapy ("controllers").

3 ol HIV exists, and these are known as 'elite controllers'.

4 mi-solid and solid foods using a temperature controller.

5 x 1 (mTORC1) protein kinase, a master growth controller.

6 evice and a 32-channel tabletop microfluidic controller.

7 fluorescence image processor) and separation controller.

8 tegrating both a circadian and a homeostatic controller.

9 nate, model-free, heuristic, and model-based controllers.

10 e independently associated with nADEs in HIV controllers.

11 otype and robust effector potential in HIV-2 controllers.

12 d with hepatic and extrahepatic nADEs in HIV controllers.

13 ith their levels in untreated progressors or controllers.

14 ut decreased in the CD4(+) TCM of 4 out of 5 controllers.

15 iable gene 2 (TRBV2) in vaccinees as well as controllers.

16 patients are predicted to behave like elite controllers.

17 y CCR5, is impaired in Nef clones from elite controllers.

18 eceiving antiretroviral therapy, and viremic controllers.

19 ressor RMs but decrease in the CD4(+) TCM of controllers.

20 parameters in untreated patients, including controllers.

21 iated with impaired protein function in some controllers.

22 the humoral immune response might vary among controllers.

23 icantly associated with increased breadth in controllers.

24 in vaccinees, whereas TRAV24 predominated in controllers.

25 rotection against CD4(+)T-cell loss in HIV-1-controllers.

26 stormwater systems with low-cost sensors and controllers.

27 We identified 149 elite controllers (0.4%) among 34 354 persons in care.

28 red LT fibrosis and CD4(+) T cells in 25 HIV controllers, 10 noncontrollers, 45 HIV-positive individu

29 hospitalizations) but were rare among elite controllers (2.7%), in whom cardiovascular hospitalizati

30 es related to the component that failed: (1) controller, (2) peripheral components, and (3) implantab

31 A total of 68 elite controllers, 68 ART recipients with suppressed viremia,

32 load-adaptive powered knee controllers, and controller adjustments affect amputees more when they wa

33 However, elite controllers also harbor a population of HIV-specific CD1

34 system is connected to an auxiliary quantum controller (ancilla) that acquires information about the

35 rdized uptake value, 1.53 [0.56]), the elite controller and ART-suppressed groups had intermediate le

36 5.9 kg (13 lbs) or 4.5 kg (10 lbs) without a controller and could hold up to 1100 bar (16000 psi) of

37 of rapamycin (mTOR) is a central cell growth controller and forms two distinct complexes: mTORC1 and

38 rential functions of CD8(+) T lymphocytes in controller and progressor RMs.

39 act of CD8(+) T lymphocyte depletion between controller and progressor SIV-infected RMs, emphasizing

40 elationship between the parameters of the PI controller and the parameters of the NMM in the form of

41 cell resistance to HIV in a cohort of elite controllers and explored transcriptional signatures asso

42 re of T-cell exhaustion in a cohort of elite controllers and in chronic progressors.

43 to human immunodeficiency virus (HIV) in HIV controllers and individuals with high exposure but seron

44 ing the requirement for external temperature controllers and overall complexity of the molecular diag

45 of soil organic matter (SOM) in forests, the controllers and pathways to stable SOM formation remain

46 leen, and the gastrointestinal tract of both controllers and progressors.

47 osed-loop interactions between robotic neuro-controllers and the physical world will bring about deep

48 should focus less on developing custom task controllers and therapy games and more on developing inn

49 ctional avidity intermediate between that of controllers and treated patients.

50 Monocytes from elite controllers (and ART recipients with suppressed viremia)

51 , including recipients with no reactivation (controllers) and those with mild (virurics) or severe (v

52 characterizing the dACC: as a monitor, as a controller, and as an economic structure.

53 an motor system can behave like a trajectory controller, and return the limb to its original trajecto

54 ould benefit from load-adaptive powered knee controllers, and controller adjustments affect amputees

55 sification (toward IgG2) was greatest in HIV controllers, and depletion of IgG2 from Ig preparations

56 These controller animals also maintained CD4(+) T cell populat

57 ting anti-CD8beta monoclonal antibody to the controller animals led to a specific decline in levels o

58 Other controller approaches include long-acting muscarinic ant

59 This device and controller are applied to build genetic circuits using s

60 treatment arms in clinical studies in which controllers are added to ICS treatment.

61 Elite controllers are hospitalized more frequently than person

62 ory Society and the US National Tuberculosis Controllers Association.

63 e findings allow for identification of HIV-1-controllers at risk for immunologic progression, and pro

64 nterfacing between rigid driving components (controller, battery, etc.) and the primarily soft body,

65 ommercial DSLR camera and a USB programmable controller board to sequentially control the illuminatio

66 he motor system can behave like a trajectory controller but only if a "desired trajectory" is the goa

67 viral efficacy are well represented in HIV-1 controllers but are rare or absent in HIV-1 progressors.

68 l load (Spearman's R=0.81, P=0.007) in acute controllers but not in acute progressors.

69 nce (1) the complexity of the neural robotic controllers can be staged as necessary, avoiding the alm

70 ity, thus recapitulating key features of the controller CD4 response.

71 ssociated factors in a large multicenter HIV controller cohort.

72 ulticenter Spanish AIDS Research Network HIV Controllers Cohort (ECRIS).

73 T)-treated HIV-infected subjects or in elite controllers compared to HIV-uninfected subjects.

74 levels were significantly elevated in elite controllers, compared with those in ART recipients with

75 The experiments indicate that the controller complexity predicted by our theory is close t

76 BK virus controllers, defined as those with episodes of BK viremi

77 ls act together to maintain the virus in HIV controllers despite effective antiviral immunity.

78 HIV controllers develop particularly efficient antiviral CD4

79 Interestingly, vaccinated SIV controllers did not present with this aberrant PD-1(hi)

80 HIV-2 controllers display a robust capacity to support long-te

81 Nef clones from acute controllers displayed a lesser ability to downregulate C

82 HIV-specific B cells derived from elite controllers displayed greater amounts of gp120-specific

83 s demonstrate that early Nef clones from HIV controllers displayed lower HLA class I and CD4 downregu

84 ; no difference occurred in the incidence of controller DM between the 2 LVADs.

85 and salmeterol and continued other pre-study controller drugs.

86 HIV-1 elite controllers (EC) are rare individuals who are able to co

87 Nef clones derived from elite controllers (EC) have been shown to be attenuated for CD

88 lly infected subjects (chronic), and 7 elite controllers (EC) were used.

89 Here, nef clones from 45 elite controllers (EC), 46 chronic progressors (CP), and 43 ac

90 d from a rare subset of HIV-1-infected elite controllers (EC), with the ability to suppress viral loa

91 out antiviral therapy have been termed elite controllers (EC).

92 tion without antiretroviral treatment (elite controllers [EC]).

93 Elite controllers (ECs) are a rare group of HIV seropositive i

94 s reduced by as much as 10,000-fold in elite controllers (ECs) compared with typical progressors (TPs

95 set of HIV-infected individuals termed elite controllers (ECs) maintain CD4(+) T cell counts and cont

96 , 40 PHI patients, 17 Chronics, and 13 Elite controllers (ECs) were studied.

97 These subjects, termed elite controllers (ECs), are known to have stronger immune res

98 B-cell responses were investigated in elite controllers (ECs), who maintain undetectable HIV levels

99 ntegration increased over time in both elite controllers (ECs; n = 8) and noncontrollers (NCs; n = 6)

100 ess viremia without treatment (termed "elite controllers" [ECs]).

101 , we calculated 5-2(+3) t precious metals in controllers embedded in all vehicle types and 220-60(+90

102 The "control of the controller" emerges from a complex interplay between PFC

103 glioma model in vivo demonstrated that this controller enables reliable and damage-free delivery of

104 e, possible reciprocal inhibition of spindle controllers entails a negative relationship between cont

105 HIV controllers experience nADEs, albeit at lower rates than

106 Types of DM included controller failure (30%), battery failure (19%), or pati

107 ssions including pilots, judges, air traffic controllers, Federal Bureau of Investigation employees,

108 encodes motivational state acting as a gain controller for adaptive behaviour in the absence of food

109 now find that Cdk1 serves as a direct master controller for NE dynein recruitment in neural stem cell

110 a test bed to develop a PI-type closed-loop controller for suppressing epileptic activity.

111 oelectric layers that act as the multi-level controller for the doping level of the sandwiched graphe

112 s, our study identifies BTBD18 as a specific controller for transcription activation through RNA poly

113 mesenchyme-derived GDF10 and GREM1 are major controllers for the topologies of rachidial and barb gen

114 CD4(+)T-bet(+) induction differentiated LTR controllers from early viremic relapsers, correlating wi

115 HIV controllers from the ANRS CODEX cohort showed a highly s

116 nd their capacity for viral control in HIV-2 controllers from the French ANRS CO5 HIV-2 cohort.

117 netic markers able to segregate stable HIV-1-controllers from those who experience CD4(+)T-cell decli

118 netic markers able to segregate stable HIV-1-controllers from those who experience CD4(+)T-cell decli

119 et > Eomesodermin (Eomes) differentiated LTR controllers from viremic relapsers and reciprocally corr

120 on the expression level of a third gene (the controller gene).

121 icense application in April 2009 to the Drug Controller General of India (DCGI), the Indian NRA respo

122 PsA-TT, MenAfriVac) was licensed by the Drug Controller General of India and prequalified by the Worl

123 In addition, elite controllers had a significantly higher proportion of CD1

124 Controllers had significant LT fibrosis and CD4(+) T-cel

125 V-infected patients and LTNPs, including HIV controllers) had significantly higher thymic function le

126 We found that elite controllers have a high proportion of potentially exhaus

127 ibute to this natural resistance: some elite controllers have CD4(+) T cells that produce high levels

128 However, some HIV-1-controllers have evidence of immunologic progression wit

129 However, controllers have evidence of ongoing inflammation, CD4(+

130 Human immunodeficiency virus (HIV) controllers have the striking ability to maintain viremi

131 However, rare patients, termed elite controllers, have a natural ability to control HIV infec

132 olling replication either spontaneously (HIV controllers [HIC]) or after progression and antiretrovir

133 sponses against HIV-1 p24 were higher in HIV controllers (HIV RNA < 2000 copies/ml) than noncontrolle

134 reduced oviduct dilatation was observed for "controllers," i.e., animals without detectable chlamydia

135 untreated individuals, including both elite controllers (ie, persons with a viral load of </=40 copi

136 arteries were connected to a pressure servo controller in a video-monitored perfusion system, and co

137 re 17% higher than the average emissions per controller in the 2012 EPA greenhouse gas national emiss

138 o determine the stabilizing region of the PI controller in the control parameter space, which provide

139 Pneumatic controllers in level control applications on separators

140 applications had higher emission rates than controllers in other types of applications.

141 Notably, stable controllers in subcortical areas are negatively related

142 They behave as local phase controllers in subwavelength dimensions for successful m

143 Complement-activation controllers, including decay accelerating factor (DAF),

144 effective CD8(+) T-cell clones from an elite controller into TCR-expressing lentivectors.

145 One of these mitotic controllers is Aurora A kinase, which is itself highly r

146 use of a LABA but not an LTRA as an "add-on controller" is associated with increased risk of asthma

147 nnels, transcriptional regulators, apoptosis controllers, kinases, and phosphatases (Phe-GluN2a, Lys-

148 induced responses and modulate these toward "controller-like" responses.

149 d or gastrointestinal biopsies from aviremic controllers (<50 copies RNA/mL) and in the context of vi

150 diversity analysis in the plasma of viremic controllers (<50-2000 copies RNA/mL).

151 otypes within Long Term Non-Progressor HIV-1-controllers ((LTNP-C), defined by maintaining CD4(+)T-ce

152 otypes within Long Term Non-Progressor HIV-1-controllers ((LTNP-C), defined by maintaining CD4(+)T-ce

153 (denileukin diftitox) in two SIVsab-infected controller macaques.

154 10(6) circulating CD4(+) T cells in the six controller macaques.

155 quently declined to undetectable levels in 6 controller macaques.

156 HIV controllers maintain a large proportion of Gag-specific

157 Background: HIV-1-controllers maintain HIV-1 viremia at low levels (normal

158 HIV-1-controllers maintain HIV-1 viremia at low levels (normal

159 It remains unclear whether elite controllers manifest T-cell exhaustion similar to subjec

160 ses in a cohort of 34 untreated HIV-infected controllers matched for viral load, with and without neu

161 t that the T cells of these particular elite controllers may be naturally resistant to HIV infection

162 These controllers may hold the key to an effective HIV vaccine

163 Interventions designed to improve asthma controller medication adherence in older adults may be e

164 within 12 months, and initiation of regular controller medication for asthma symptoms within 12 mont

165 ratory symptoms, and/or use of asthma rescue/controller medication in the preceding 12 months on repe

166 ion-to assess the effects of selected asthma controller medication use (leukotriene antagonists and i

167 Adherence to pediatric asthma controller medication, measured as the medication posses

168 with poorly controlled asthma while taking a controller medication, use of a soy isoflavone supplemen

169 aled corticosteroids and at least one second controller medication.

170 or placebo as add-on therapy to conventional controller medication.

171 take fewer than half of prescribed doses of controller medication.

172 or oral prednisone (P < .0001) or additional controller medications (P = .001), as well as longitudin

173 y is associated with low adherence to asthma controller medications among older adults.

174 Eligibility for stepping down asthma controller medications included no hospitalizations or e

175 Treatment with controller medications might not protect but rather wors

176 Asthma guidelines suggest reducing controller medications when asthma is stable.

177 the safety and costs of stepping down asthma controller medications with maintaining current treatmen

178 inhaled corticosteroid dose, total number of controller medications, and total blood eosinophil count

179 dications, or medium-dose ICS with 2 or more controller medications, in the first phase III trial of

180 d-on therapy to high-dose ICS with 1 or more controller medications, or medium-dose ICS with 2 or mor

181 Other controller medications, such as long-acting bronchodilat

182 inal asthma study and effect modification by controller medications.

183 high-dose inhaled corticosteroids plus other controller medications.

184 ntribute to differential responses to asthma controller medications.

185 older with symptomatic asthma while taking a controller medicine and low dietary soy intake were rand

186 high-dose inhaled corticosteroids plus other controller medicines.

187 Our novel motor controller mimicked in vivo inertial/gravitational loadi

188 tional-integral-derivative (PID) temperature controller minimised temperature based drifts.

189 t a sensor module, an actuator module, and a controller module.

190 subdivided as follows: naive (n = 63), elite controllers (n = 19), long-term nonprogressors (n = 7),

191 The inability of elite controller Nef to fully remove CD4 from the surface of i

192 expression of the cytokine and the upstream controller NLRP3.

193 We present observations from a HIV-1 elite controller, not treated with combination antiretroviral

194 ext of regulation of profilin (Pfn), a major controller of actin dynamics and actin cytoskeletal remo

195 upport a model in which T-bet is a universal controller of antiviral immunity across multiple immune

196 agues find that interleukin-33 is a critical controller of brown and beige adipocyte thermogenesis.

197 (TOR), a highly conserved kinase and central controller of cell growth.

198 cterization of the role of inflammation as a controller of enteric mucosal tissue patterning requires

199 copy number variation of MSR1s is a generic controller of gene expression and promises to provide ne

200 r metabolism is increasingly recognized as a controller of immune cell fate and function.

201 These findings reveal miR-301b as a new controller of inflammatory response by repressing c-Myb

202 complement system, traditionally known as a controller of innate immunity, now stands as a multiface

203 athways involved in regulation of the master controller of iron metabolism, the hormone hepcidin, in

204 PKCdelta/p38delta signaling, a key controller of keratinocyte proliferation and differentia

205 umferentially organized fibers act as a main controller of longitudinal growth, we show that the fibe

206 ium, emphasizing the importance of pVHL as a controller of mitotic fidelity in vivo.

207 PP2A is a master controller of multiple inflammatory signaling pathways.

208 Soil fertility is a key controller of mycorrhizal costs and benefits and the Law

209 d with innate immunity, is emerging as a key controller of nonimmune systems including in development

210 pendent reduction in the level of p53, a key controller of p21(Cip1) gene expression.

211 es allows it to act as a cellular sensor and controller of PM phosphoinositides, thereby influencing

212 ribbles proteins has emerged as an important controller of signalling via regulating the activity of

213 onmental social signals as a third, parallel controller of sleep homeostasis and sleep pressure.

214 osed strategy uses weight maps to inform the controller of the tendency for models to differ in their

215 on and suggests that LRP1 is a major traffic controller of the two aggrecanases, especially under inf

216 n this study, we identified LGR4 as a master controller of Wnt/beta-catenin signaling-mediated breast

217 The Ras-superfamily GTPases are central controllers of cell proliferation and morphology.

218 ting for the expression of these TCRs in HIV controllers of diverse genetic backgrounds.

219 BHLH100, BHLH101 and BHLH039 and the master controllers of Fe deficiency responses PYE and BTS were

220 AP1 transcription factors are important controllers of gene expression in the epidermis, and alt

221 k base pairing, have recently emerged as key controllers of genome duplication.

222 most chronically infected individuals, elite controllers of HIV retain CD8(+) T-cell polyfunctionalit

223 In contrast, natural controllers of HIV-1 had the highest absolute number of

224 uses was assessed in 163 clade B spontaneous controllers of HIV.

225 highlighting features that make them potent controllers of infection in nonlymphoid tissues.

226 nsights on the functioning of these critical controllers of innate and adaptive immunity.

227 sory integration, and identify direct neural controllers of MCH neurons.

228 hese results establish TAM receptors as both controllers of microglial physiology and potential targe

229 te that unconventional T cells represent key controllers of neutrophil-driven innate and adaptive res

230 RM2) and CDKB1;1 when upregulated act as key controllers of stomatal adaptation to elevated CO2 .

231 the T cell antigen receptor and c-Myc as key controllers of T cell protein O-GlcNAcylation via regula

232 e of Interferon regulatory factors (IRFs) as controllers of the human Langerhans cell response to epi

233 Elite controllers or suppressors (ES) are HIV-1-infected patie

234 Elite controllers or suppressors (ESs) are HIV-1-infected indi

235 ive antiretroviral therapy (ART) and 6 elite controllers or suppressors who were maintaining undetect

236 pathway components were found to act as key controllers orchestrating the cellular response in kerat

237 Within the group not treated with a daily controller, OW children had more asthma symptom days (90

238 G NEI, released in 2014); the average of 2.7 controllers per well observed in this work is higher tha

239 observed in this work is higher than the 1.0 controllers per well reported in the 2012 GHG NEI.

240 ost and viral factors that contribute to the controller phenotype may identify new strategies to desi

241 We demonstrate that a subgroup of elite controllers possess CD4(+) T cells that are specifically

242 ledge, we show for the first time that HIV-2 controllers possess CD8(+) T cells that show an unusuall

243 More than half of the controllers recorded emissions of 0.001 scf/h or less du

244 differentially regulated in resistant elite controllers relative to healthy controls.

245 Average methane emissions per controller reported in this work are 17% higher than the

246 Grouping animals into "ascenders" and "controllers" revealed that elevated early T cell respons

247 ered knee prosthesis with two pre-programmed controller settings (i.e. for load and no load).

248 erformance did not significantly change with controller settings.

249 Following expansion, controllers showed a greater increase in the overall bre

250 thermore, CXCR5(+) CD4(+) T cells from elite controllers showed a stronger ex vivo capacity to induce

251 expanded Gag-specific CD4(+) T cells in HIV controllers showed higher levels of expression of the cy

252 r, we found that the immune responses of HIV controllers showed intrinsically better helper activity

253 Elite controllers spontaneously suppress human immunodeficienc

254 current living nervous systems; (2) robotic controller states are fully observable, avoiding the eno

255 th asthma necessitating treatment with daily controller (Step 2) therapy.

256 bitory activity of CD8(+) T cells from elite controllers than from HIV-1 progressors supports the cru

257 activation (measured by Ki-67 expression) in controllers than in progressors.

258 loads and CD4(+) T lymphocyte activation in controllers than in progressors.

259 s II tetramer-positive CD4(+) T cells in HIV controllers than progressors (P = 0.0001), and these exp

260 eased virus replication, more prominently in controllers than progressors, which correlated inversely

261 reports the development of bnAbs in an elite controller that, along with the help of T cells, were as

262 d corticosteroids are the most commonly used controller therapies for asthma, producing treatment res

263 the United States of improving adherence to controller therapies in adults with uncontrolled asthma

264 in both groups received standardized asthma-controller therapies that were used in a simultaneous, f

265 ater than or equal to 30 years old receiving controller therapy experienced treatment failures.

266 nction and asthma control, but the effect of controller therapy on these fluctuations is unknown.

267 atopy were associated with high-dose asthma controller therapy requirement.

268 not respond to the most commonly prescribed controller therapy, inhaled corticosteroids (ICS).

269 In preschool children off controller therapy, OW is associated with greater asthma

270 lmonary physiology despite ongoing high-dose controller therapy.

271 ent treatment failure and may be modified by controller therapy.

272 With a radio-frequency (RF) power source and controller, this implant produces sufficient light power

273 metric or substoichiometric amount of chiral controller to deliver optically active alcohols.

274 These results confirmed the ability of the controller to modulate the drug delivery dosage within a

275 cade generator, but also uses a time-optimal controller to yield the desired saccade magnitude.

276 This paper uses individual micro controllers to emulate p-bits, and we present results fo

277 city of HIV-specific CD8(+) T cells in elite controllers to inhibit HIV infection.IMPORTANCE The grea

278 hospitalization rates and causes among elite controllers to those of immunologically intact persons w

279 78% had a controller treatment.

280 f day and night symptoms, exacerbations, and controller usage.

281 In elite controllers, virus was detected primarily in foci in the

282 itochondrial dehydrogenases, as an open-loop controller, was investigated in isolated cardiac and ske

283 For three elite controllers, we observed increased production of MIP-1al

284 that CD8(+) T cells from 2 out of 4 viremic controllers were capable of effectively eliminating reac

285 ic and immunological data collected from the controllers were included in a multivariate model to ass

286 Emissions from 377 gas actuated (pneumatic) controllers were measured at natural gas production site

287 leads to specifying a time-varying feedback controller which both generates the movement and can opt

288 such as syringe pumps, valves, and pressure controllers which could be set up in a very compact over

289 0, RANTES, and TNFalpha, was observed in HIV controllers who developed bNAbs.

290 ifferent disease phenotypes, including elite controllers, who spontaneously control HIV-1 viremia to

291 inhaled corticosteroids plus >/=1 additional controller with or without daily oral corticosteroids) t

292 movement matching predictions of the optimal controller with state-dependent sensory noise.

293 es of HIV-specific antibodies in a cohort of controllers with and without protective HLA-B alleles in

294 her IFN-gamma (p=0.02) levels than the HIV-1-controllers with diminished CD4(+)T-cell numbers.

295 HIV RNA > 10,000 copies/ml), particularly in controllers with low but detectable viremia (HIV RNA 75-

296 mals (10 progressors with high viremia and 5 controllers with low viremia) were CD8 depleted by i.v.

297 Previous studies have shown that elite controllers with minimal effector T cell responses harbo

298 en the specific repertoires of vaccinees and controllers, with the sharing of TRAV24 and TRBV2 public

299 Data on nADEs were recorded for 320 HIV controllers within the multicenter Spanish AIDS Research

300 In contrast, viremic controllers without protective HLA class I alleles posse